UCHealth has partnered with a new, Denver-based health innovation company to develop revolutionary technology that it and other large health care systems will use to monitor patients’ vital signs remotely after they have left the hospital.
BioIntelliSense recently secured FDA clearance of the BioSticker, an on-body device that is expected to reduce health care costs, help improve patients’ outcomes and reduce readmissions. The platform combines improved patient experience with medical-grade accuracy and cost-effective data delivery.
“We are at the inception of a remarkable new era in health care that will employ medical-grade sensor technologies to effortlessly capture remote patient data and generate personalized clinical intelligence,” said Dr. James Mault, CEO of BioIntelliSense.
About three inches in length and an inch wide, the BioSticker is placed on a patient’s chest and continuously monitors vital signs and symptomatic events. These measurements can include respiratory rate, resting heart rate, skin temperature, gait, body position and more. Remote patient monitoring with the BioSticker has potential to allow a doctor to send a patient home from the hospital earlier and continue monitoring his or her health. Patients with chronic conditions will be able to be continuously monitored from their homes, making it possible for doctors to intervene even before the patient realizes they’re sick.
Through a strategic partnership with BioIntelliSense, UCHealth and its CARE Innovation Center helped develop and test the BioSticker and will be the first in the nation to begin using it in patient care. The data will be continuously fed back to UCHealth’s Virtual Health Center. Artifical intelligence-driven algorithms will alert the medical teams in the Virtual Health Center should they need to intervene.
“The future of health care will see the lines blurred between the hospital, clinic and home,” said Dr. Richard Zane, UCHealth chief innovation officer and chair of emergency medicine at the University of Colorado School of Medicine. “The use of the BioSticker device for continuous health monitoring enables us to monitor a patient in their home and recognize when a patient may have an exacerbation of illness even before they notice symptoms. This may reduce hospitalizations, reduce emergency department visits, and shorten hospital stays, significantly reducing health care costs for these patients.”
Today, a doctor might keep a patient admitted or on observation status for an extra day just to make sure he or she is healthy. But soon, the patient may be sent home from the emergency department or hospital earlier with a BioSticker to monitor their health. By avoiding some hospital readmissions, reducing emergency department visits and allowing some patients to be discharged earlier, the BioSticker could significantly reduce the cost of care for certain patients.
“Not only will we be reducing health care costs significantly, but we’ll be able to monitor the patient for a longer period of time – up to 30 days on the current battery – helping reduce readmissions, reduce return visits to the hospital, and improve quality,” said Steve Hess, UCHealth chief information officer.
Physicians, data specialists and electronic medical record experts from the University of Colorado Anschutz Medical Campus and UCHealth have worked with BioIntelliSense to help develop the clinical applications for the BioSticker along with the integration of data with the Virtual Health Center. The first clinical uses of the sticker will launch in 2020.
“We are proud and excited to be working with the innovative teams at UCHealth and the University of Colorado Anschutz Medical Campus,” Dr. Mault said. “It is a remarkable collaboration and clinical proving ground for our continuous monitoring and predictive data services platform. UCHealth has made it possible for a company like BioIntelliSense to rapidly accelerate the development of our technology, as well as to optimize its clinical validation.”